Ellagic Acid-Gold Nanoparticle Complex as Anticancer Agent in Triple-Negative Breast Cancer Cells

被引:0
|
作者
Unnikrishnan, Jyothsna [1 ]
Hegde, Mangala [2 ]
Girisa, Sosmitha [2 ]
Satpati, Priyadarshi [1 ]
Kunnumakkara, Ajaikumar B. [2 ]
机构
[1] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Computat Biol Lab, Gauhati 781039, Assam, India
[2] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Canc Biol Lab, Gauhati 781039, Assam, India
关键词
Gold nanoparticle; phytochemicals; ellagic acid; triple-negative breast cancer; GREEN SYNTHESIS; NATURAL-PRODUCTS; KAPPA-B; PREVENTION; PHYTOCHEMICALS; DELIVERY; BIOAVAILABILITY; PROTEINS; SILVER; SHAPE;
D O I
10.1142/S179398442450003X
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Triple-negative breast cancer (TNBC) is the most aggressive sub-type of breast cancer, mainly affecting premenopausal women. As it neither expresses hormone receptors nor overexpresses HER2 receptors, it is difficult to tackle this deadly disease effectively. It is a well-known fact that phytochemicals have remarkable therapeutic potential in the prevention and treatment of different disorders. One of the well-known phytochemicals, ellagic acid (EA) has shown better efficacy in the prevention and treatment of cancer in many preclinical and clinical settings. Therefore, in this study, ellagic acid gold nanoparticles (EA-AuNp) were synthesized and characterized to passively target TNBC cells through EPR effect. EA-AuNp were prepared using the direct reduction method and characterized by UV-Visible spectroscopy, DLS, XRD, EDX, TEM and FT-IR spectra. We found that it significantly suppressed the TNBC cell proliferation (IC50 12 mu g/ml) compared to EA alone (IC50 36 mu g/ml). Flow cytometry and live and dead assays revealed that EA-AuNp induced more cell death in TNBC cells compared to EA alone. Further, western blot analysis substantiated that EA-AuNp induced apoptosis by regulating the expression of Bcl-2, survivin, caspase 3 and caspase 9. In conclusion, EA-AuNp has high anti-cancer potential and additional preclinical and clinical studies are highly recommended.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] An ER-α36 monoclonal antibody exhibits anticancer activity in triple-negative breast cancer cells
    Lin, Qingcong
    Zhou, Junma
    Wang, Jing
    Wang, Zonghui
    Wang, Jun
    Chen, Feng
    Qian, Xueming
    Shang, Xiao
    Bao, Jun
    Wang, Zhaoyi
    Meng, Kun
    CANCER RESEARCH, 2015, 75
  • [42] The anticancer mechanism of action of selected polyphenols in triple-negative breast cancer (TNBC)
    Farghadani, Reyhaneh
    Naidu, Rakesh
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 165
  • [43] Phytoestrogen Coumestrol as an Anticancer Therapy Against Triple-Negative Inflammatory Breast Cancer
    Rodriguez-Martir, Keishla
    Colon, Jose
    Ortiz, Ayeisha
    Peterson, Esther
    FASEB JOURNAL, 2020, 34
  • [44] The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells
    Mendonca, Patricia
    Darwish, Ahmed G.
    Tsolova, Violeta
    El-Sharkawy, Islam
    Soliman, Karam F. A.
    ANTICANCER RESEARCH, 2019, 39 (08) : 4043 - 4053
  • [45] Gold(III)-P-chirogenic complex induces mitochondrial dysfunction in triple-negative breast cancer
    Olelewe, Chibuzor
    Kim, Jong Hyun
    Ofori, Samuel
    Mertens, Randall T.
    Gukathasan, Sailajah
    Awuah, Samuel G.
    ISCIENCE, 2022, 25 (05)
  • [46] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)
  • [47] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [48] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [49] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [50] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436